ABBV vs GS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Goldman Sachs Group, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
The Goldman Sachs Group, Inc. · Financial Services
$1,045.91
-45.0% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
GS trades at a lower forward P/E
(23.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GS |
| Current Price |
$261.07 |
$1,045.91 |
| Fair Value Estimate |
$264.30 |
$575.25 |
| Upside to Fair Value |
+1.2%
|
-45.0%
|
| Market Cap |
$461.3B |
$308.6B |
| Forward P/E |
128.0x
|
23.6x
|
| EV / EBITDA |
31.0x
|
15.9x
|
| Price / Sales |
7.3x
|
3.1x
|
| Price / FCF |
22.1x
|
-7.4x
|
| Revenue Growth YoY |
+12.4%
|
-35.0%
|
| Gross Margin |
70.7%
|
47.4%
|
| Operating Margin |
27.6%
|
17.8%
|
| Return on Equity |
68.0%
|
15.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. Despite its strong brand and competitive position in financial capital markets, the company currently faces significant headwinds as evidenced by a 35% decline in revenue and a 100% drop in earnings in the most recent quart…
Accumulation Zones
| Metric |
ABBV |
GS |
| Zone Low |
$198.23 |
$431.44 |
| Zone High |
$224.66 |
$488.96 |
| In Buy Zone? |
No
|
No
|